Flash Finance

Beta Drugs LimitedBETACorporate

Pharmaceuticals - Indian - Bulk Drugs Latest results: Jun 2026 7 quarters of data
Consolidated Standalone
₹1,783.00
MCap ₹1,800 Cr · P/E 31.4
Beta Drugs Limited — Stock analysis & AI research Beta Drugs Limited — Multibagger AI analysis Beta Drugs Limited — Seasonality — best & worst months Beta Drugs Limited — Technical indicators & charts Beta Drugs Limited — Technical setup — score, trend, support & resistance Beta Drugs Limited — Live exchange announcements
📋 High ROE Stocks📋 Stocks With Strong Quarterly Results 📈 Gap Up Stocks 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹126 Cr
Sales · Jun 2026
+25.5% YoY
₹27 Cr
Operating Profit · Jun 2026
+36.8% YoY
21.8%
OPM % · Jun 2026
+9.0% YoY
₹16 Cr
Net Profit · Jun 2026
+31.7% YoY
₹14.78
EPS · Jun 2026
+27.5% YoY

📝 Beta Drugs Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Beta Drugs Limited reported revenue of ₹126 crore for the quarter ended June 2026 (Q1 FY27), up 25.5% from ₹100 crore in the same quarter last year, and up 33.6% sequentially over the March 2026 quarter.

Net profit rose 31.7% year-on-year to ₹16 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹14.78.

Operating profit stood at ₹27 crore — an operating margin (OPM) of 21.8%, compared with 20.0% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Beta Drugs Limited posted revenue of ₹487 crore, with a net profit of ₹53 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹513 crore with a net profit of ₹57 crore.

Valuation snapshot

At the current price of ₹1,783.00, BETA has a market capitalisation of ₹1,800 crore and a trailing P/E of about 31.4.

Within the Pharmaceuticals - Indian - Bulk Drugs industry, it is the 4th-largest of the 11 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 58.91%, foreign institutional investors (FIIs) 1.37%, domestic institutional investors (DIIs) 6.45%, public shareholders 33.27% of Beta Drugs Limited.

Promoter holding slipped from 59.10% to 58.91% over the latest period.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹1,800 Cr
Current Price ?
₹1,783.0
P/E ?
31.42below ind
Industry P/E ?
32.10
P/B ?
7.35
P/S ?
3.51
P/FCF ?
-112.49
Enterprise Value ?
₹1,948 Cr
EV/EBITDA ?
18.49
PEG ?
2.86
Earnings Yield ?
4.3%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹513 Cr
OPM ?
20.5%
Profit after tax (TTM) ?
₹57 Cr
EPS (TTM) ?
₹56.74
ROCE ?
19.0%
ROE ?
23.4%
ROA ?
11.5%
Growth
Sales — latest qtr ?
₹126 Cr
PAT — latest qtr ?
₹16 Cr
YoY qtr sales growth ?
25.5%
YoY qtr profit growth ?
31.7%
Sales growth (3y) ?
19%
Sales growth (5y) ?
27%
Profit growth (3y) ?
11%
Profit growth (5y) ?
29%
Financial Health
Debt ?
₹148 Cr
Debt to Equity ?
0.60
Interest Coverage ?
4.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
58.91%
Change in promoter holding ?
-7.82%
Pledged percentage ?
N/A
Market
Return 3 months ?
-20.0%
Return 6 months ?
29.6%

🗓️ Quarterly results (7 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 88941002049094126 +25.5% +33.6%
Operating Profit 18172041191827 +36.8% +54.8%
Other Income -1236232 -47.2% -45.2%
Interest 2337443 -14.6% -35.0%
Depreciation 3448454 +8.6% -9.5%
Profit Before Tax 12121632101222 +37.8% +86.3%
Net Profit 9912249916 +31.7% +74.6%
EPS 8.868.9511.5947.388.408.9314.78 +27.5% +65.5%
OPM % 20.9% 18.5% 20.0% 20.1% 21.5% 18.8% 21.8% +9.0% +16.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric Prev FY FY26 TTM YoY %
Sales — ₹487 Cr ₹513 Cr —
Operating Profit — ₹98 Cr ₹105 Cr —
OPM % — 20.11% 20.55% —
NPM % — 10.98% 11.17% —
Other Income — ₹14 Cr ₹13 Cr —
Depreciation — ₹21 Cr ₹22 Cr —
Interest — ₹18 Cr ₹18 Cr —
EBIT — ₹77 Cr ₹84 Cr —
PBT — ₹70 Cr ₹76 Cr —
Tax — ₹11 Cr ₹11 Cr —
Net Profit — ₹53 Cr ₹57 Cr —
EPS — ₹76.30 ₹79.49 —
Material Cost — ₹141 Cr ₹192 Cr —
Employee Cost — ₹38 Cr ₹58 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 10101010 +0.0%
Reserves 113148187235 +25.7%
Borrowings 2015138148 +7.2%
Other Liabilities 5582101103 +2.0%
Total Liabilities 198254436496 +13.8%
Fixed Assets 636589125 +40.4%
CWIP 0000 —
Investments 1000 —
Other Assets 135190347371 +6.9%
Total Assets 198254436496 +13.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 23313637 +2.8%
Cash from Investing Activity -19-14-36-51 -41.7%
Cash from Financing Activity -2-7118-8 -106.8%
Net Cash Flow 29118-22 -118.6%
Free Cash Flow 519-1-16 -1500.0%
CFO/OP 44%52%48%49% +2.1%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 10198103113 +9.7%
Inventory Days 106122127159 +25.2%
Days Payable 139145152172 +13.2%
Cash Conversion Cycle 687579100 +26.6%
Working Capital Days 73808297 +18.3%
ROCE % 34%33%27%19% -29.6%

👥 Shareholding (latest 5 periods)

Metric Sep 2025Dec 2025Mar 2026May 2026Sep 2026 % Chg
Promoters 66.73%64.90%64.63%59.10%58.91% -0.3%
FIIs 0.90%1.14%1.16%2.95%1.37% -53.6%
DIIs 0.29%1.90%2.15%6.01%6.45% +7.3%
Public 32.07%32.07%32.06%31.93%33.27% +4.2%
No. of Shareholders 3,1843,6944,7365,02710,145 +101.8%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs · 11 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SMSPHARMA SMS Pharmaceuticals ₹442.45 4,144 39.7 898 102 19.3% 11.4% 13.3% 48.6% 5.6% -1.4%
2 AARTIDRUGS Aarti Drugs ₹428.30 3,909 20.5 2,678 191 12.4% 7.1% 7.5% 16.3% 18.9% -7.2%
3 HIKAL Hikal ₹229.83 2,834 — 1,734 -34 13.4% -2.0% -8.0% -154.4% 6.0% 67.0%
4 BETA Beta Drugs ₹2,064.90 2,084 37.5 513 57 20.5% 11.2% — — 25.5% 31.7%
5 NGLFINE NGL Fine-Chem ₹2,786.60 1,722 30.1 536 57 15.6% 10.6% 36.0% 123.2% 33.6% 99.1%
6 ANUHPHR Anuh Pharma ₹92.99 932 21.1 779 44 8.6% 5.7% 16.5% -12.8% 4.2% 42.8%
7 INFINIUM Infinium Pharma ₹222.95 347 31.2 190 14 11.3% 7.2% — — 45.2% 166.7%
8 AAREYDRUGS Aarey Drugs ₹98.71 329 67.1 415 4 1.6% 1.0% -0.4% 12.3% -56.3% -25.3%
9 PAR Par Drugs ₹128.90 159 10.9 109 14 18.3% 13.3% 2.7% -1.9% 20.1% 41.6%
10 KREBSBIO Krebs Biochemicals ₹57.94 125 — 25 -14 -10.0% -55.9% -45.2% 37.1% 27.4% 53.3%
11 VILINBIO Vilin Bio ₹18.00 27 14.2 42 2 7.6% 4.6% — — 215.9% 1680.0%
❓ Frequently asked questions
What was Beta Drugs Limited's revenue in Q1 FY27?
Beta Drugs Limited reported revenue of ₹126 crore for the quarter ended June 2026 (Q1 FY27), up 25.5% from ₹100 crore in the same quarter last year, and up 33.6% sequentially over the March 2026 quarter.
What was Beta Drugs Limited's net profit in Q1 FY27?
Net profit rose 31.7% year-on-year to ₹16 crore, from ₹12 crore. Earnings per share (EPS) came in at ₹14.78.
What is BETA's market capitalisation and P/E ratio?
At the current price of ₹1,783.00, BETA has a market capitalisation of ₹1,800 crore and a trailing P/E of about 31.4.
Who owns Beta Drugs Limited? (shareholding pattern)
As of Sep 2026, promoters held 58.91%, foreign institutional investors (FIIs) 1.37%, domestic institutional investors (DIIs) 6.45%, public shareholders 33.27% of Beta Drugs Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI